Recent Winners


+180%
PLX
Alert Price: $0.36
High Price: $1.01
Results: 180% in 40 Days
+157%
OREX
Alert Price: $1.81
High Price: $4.65
Results: 157% in 36 Days
+133%
CGIX
Alert Price: $1.50
High Price: $3.50
Results: 133% in 85 Days
+91%
GBT
Alert Price: $15.85
High Price: $30
Results: 91% in 41 Days
+90%
LPTH
Alert Price: $1.40
High Price: $2.66
Results: 90% in 69 Days
+87%
ARIA
Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
+72%
TRR
Alert Price: $10.10
High Price: $17.38
Results: 72% in 51 Days
+64%
MBLY
Alert Price: $37.68
High Price: $61.73
Results: 64% in 67 Days
+58%
AAOI
Alert Price: $28.22
High Price: $44.46
Results: 58% in 60 Days
+58%
XGTI
Alert Price: $1.47
High Price: $2.32
Results: 58% in 29 Days
+55%
EXAS
Alert Price: $15.10
High Price: $23.40
Results: 55% in 37 Days
+47%
CPRX
Alert Price: $1.20
High Price: $1.76
Results: 47% in 60 Days
+45%
PTLA
Alert Price: $25.06
High Price: $36.40
Results: 45% in 67 Days
+44%
VRTX
Alert Price: $79.39
High Price: $114.06
Results: 44% in 51 Days
+38%
EDIT
Alert Price: $18.24
High Price: $25.09
Results: 38% in 55 Days
+36%
CYNO
Alert Price: $48.25
High Price: $65.90
Results: 36% in 28 Days
+35%
NKTR
Alert Price: $13.75
High Price: $18.50
Results: 35% in 51 Days
+32%
EBS
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
+31%
ATVI
Alert Price: $37.05
High Price: $48.42
Results: 31% in 68 Days
+27%
ILMN
Alert Price: $134.56
High Price: $171.52
Results: 27% in 55 Days
+27%
ICHR
Alert Price: $13.40
High Price: $17.04
Results: 27% in 22 Days
+27%
QRVO
Alert Price: $55.67
High Price: $70.64
Results: 27% in 73 Days
+25%
WILN
Alert Price: $1.58
High Price: $1.98
Results: 25% in 72 Days
+25%
BMA
Alert Price: $70.05
High Price: $87.41
Results: 25% in 61 Days
+23%
CNAT
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
+23%
PEIX
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
+21%
KATE
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
+20%
REPH
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
+20%
GNRT
Alert Price: $4.49
High Price: $5.37
Results: 20% in 62 Days
+20%
SN
Alert Price: $11.24
High Price: $13.46
Results: 20% in 15 Days
+20%
DXCM
Alert Price: $63.23
High Price: $76.06
Results: 20% in 68 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.

Trading Lessons

Mainstream Financial News

Archives

Mylan Laboratories Launches Generic Trilafon Tablets

April 20, 2017: Mylan Laboratories Inc announced the U.S. launch of Perphenazine Tablets USP, 2 mg, 4 mg, 8 mg and 16 mg, a generic version of the reference listed drug, Trilafon Tablets 2 mg, 4 mg, 8 mg and 16 mg, originally marketed by Schering. Mylan received final approval from the U.S. Food and (Read More….)

Fusion Telecommunications Gets $2.1 Million Contract From Healthcare Provider

April 20, 2017: Fusion Telecommunications International has secured a $2.1 million, five year cloud solutions contract with a leading health system. The company cited Fusion’s productivity-enhancing cloud communications and collaboration services, integrated cloud connectivity with Quality of Service guarantees, experienced, live technical support and exemplary reputation for providing a superior customer experience.

Fusion’s team of (Read More….)

Citigroup Names Medtronic As New Top Pick

April 07, 2017: Citigroup names Medtronic as their new Top Pick. Citigroup also reiterates their Buy rating on the stock. Citigroup says semi-annual survey of 40 US endocrinologists has come back significantly more positive for MDT, with: (1) big share gain expectations for both the pumps and CGM segments, and (2) positive read-through for ability (Read More….)

Opko Receives FDA Orphan Drug Status For Oligonucleotide

March 22, 2017: OPKO Pharmaceuticals LLC, a subsidiary of OPKO Health, Inc. announces that the Company has received orphan drug designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development for OPKO’s oligonucleotide-based AntagoNAT (CUR-1916) for the treatment of Dravet Syndrome. Currently, there is no approved treatment for Dravet Syndrome in (Read More….)

Sell Exact Sciences For a 55% Win!

March 4, 2017: Sell Exact Sciences for a 55% win in 37 days. Congratulations if you were able to make money on the trade and always remember to sell your positions before you get the sell alert from me. I review more than 200 open stock positions over the weekend when I have time and (Read More….)

Medical Device Markets To Benefit From Big VA IoT Push

The Department of Veterans Affairs is on the cutting edge of IoT medical devices. This is great news for medical device stocks and more specifically telehealth companies like Koninklijke Philips (PHG), Teladoc (TDOC), Medtronic (MDT), and more.

Below is Susan Perez with the Department of Veterans Affairs talking about how IoT and medical devices a (Read More….)

Bellicum Pharmaceuticals Updates On Clinical BP-004 Study

February 22, 2017: Bellicum Pharmaceuticals announced updated clinical results of the BP-004 study. To date, 122 pediatric patients have undergone treatment with BPX-501. Investigators reported on 91 patients with 100 days of follow-up, 73 patients with six months, and 45 patients with more than one year of follow-up. Genetic blood diseases (n=54) include SCID (Severe (Read More….)

AMN Healthcare Beats on Earnings and Revenue

February 16, 2017: AMN Healthcare Services reports Q4 EPS of $0.62 versus the $0.55 estimate. Revenue also beat coming in at $487.9 million versus the $477 million estimate. Adjusted EBITDA came in at $60.9 million which is up +29.9% YoY.

January 22, 2017: Benchmark Company initiates coverage of AMN AMN Healthcare with a Buy (Read More….)

Centene Beats on Earnings and Revenue

February 7, 2017: Centene reports Q4 EPS of $1.19 versus the $1.12 estimate. Revenue also beat coming in at $11.9 billion versus the $10.9 billion estimate. Quarter-end at-risk managed care membership came in at 11.44 million versus 5.1 million last year representing an increase of 223% YoY, nice!

January 5, 2017: Centene Corporation announced (Read More….)

Jefferies Reiterates TherapeuticsMD As Top Small-cap Pick For 2017

January 25, 2017: Jefferies reiterates TherapeuticsMD with a Buy rating and a price target of $18. Jefferies says that the investor tour of local compounding pharmacy provided unique insights into ‘001 market opportunity and reinforced our view that the bioidentical E+P VMS market is at a minimum 5.1M scrips or $714-$893M in sales (assumes 100% (Read More….)

Avondale Partners Raised McKesson To Market Outperform

January 17, 2017: Avondale Partners raised McKesson to Market Outperform from Market Perform.

January 17, 2017: McKesson agrees to $150 million settlement with DOJ over failure to report suspicious orders of drugs. The nationwide settlement requires McKesson to suspend sales of controlled substances from distribution centers in Colorado, Ohio, Michigan and Florida for multiple years. (Read More….)

Novo Nordisk Marketing Authorization Granted by European Commission For Fiasp

January 10, 2017: Novo Nordisk A/S B announces marketing authorization granted by European Commission for Fiasp for treatment of diabetes in adults. Novo Nordisk expects to launch Fiasp in the first European countries in the first half of 2017. The authorisation covers all 28 European Union member states.

Fiasp is the brand name for fast-acting (Read More….)

Alexion Pharmaceuticals Seeing Heavy Call Activity

January 4, 2017: Seeing heavy call activity in Alexion Pharmaceuticals: 2,000 Aug $140 calls traded at $12.80. I wonder if the heavy call activity has anything to do with the takeover rumors that were circulating on December 20, 2016, about Alexion Pharmaceuticals?

December 22, 2016: Leerink defending Alexion Pharmaceuticals; Reiterates outperform rating and price target (Read More….)

The Ensign Group Purchases 15 Wisconsin Assisted Living Assets

December 27, 2016: The Ensign Group acquired the underlying real estate of fifteen assisted living operations located throughout Wisconsin. An Ensign subsidiary has been operating each facility since August 2015 under a lease with a purchase option.

The CEO said, “With our ownership of this real estate, we are excited about deepening our commitment to (Read More….)

Biotechnology Won Big On Election Night Here’s Why

Hillary Clinton and Democrats promised to wage war on pharmaceutical companies and do things like price controls on drugs and products of the biotechnology industry.

In California, there was a ballot measure to impose price controls on the sale of pharmaceutical drugs in the state.

Both Hillary Clinton’s probability of winning, and California’s (Read More….)

Here Comes Inflation FINALLY! Traders Focus On Earnings

We have enough data to say that inflation is finally trending higher.

In case you are wondering why inflation moving higher is important, please review this.

The less volatile sticky CPI confirms the uptrend.

ObamaCare has exploded the cost of medical care higher.

Medical care commodities, which are prescription and (Read More….)

A Macroeconomic Analysis of ObamaCare

ObamaCare has created massive shortages within the healthcare sector. In cities, it is common to wait many hours before being seen as hospitals have a shortage of beds. Doctors have stopped taking new patients as they are overwhelmed by the numbers of people coming to see them. Let’s examine what happened from a macroeconomics perspective.

(Read More….)

Rising Wages and Rise of the Machines

As wages rise, more and more business owners are turning to machines instead of human labor. President Obama and Democrats have spent the last 8 years replacing high-paying jobs in the manufacturing sector with low-paying jobs in the services and health care sectors. But in all fairness, both Republicans and Democrats are to blame for (Read More….)

Six IPOs Could Come Next Week

Last week was the biggest IPO week of the year with four companies launched. Next week could be even more significant as six companies are on the IPO calendar.

The IPO market is looking healthy. Below is a chart of the Renaissance IPO Index which is a market-cap-weighted basket of newly public companies.

The (Read More….)

Terrifying US Pension Fund Charts

Pension funds in the US could be close to a collapse. There is an estimated $1.9 trillion shortfall in U.S. state and local pension funds because of low-interest rates and a sideways US stock market. Even stocks falling overseas is a problem for pension funds.

Credit Suisse published the chilling chart below on the funding (Read More….)

ObamaCare Lie Costing Americans Everything

The ObamaCare lie that health care premiums would fall for hard working Americans is so insidious, I fully expect Democrats and Clinton to lose to Trump in November.

Here is Obama lying to the American people about how ObamaCare would lower working people’s health care premiums:

If you haven’t already heard from your employer, (Read More….)

Sectors Warn S&P 500 Brexit Bounce Could Be Over Soon

Sector rotation is flashing a big red warning signal that the post-Brexit bounce could be over as soon as next week. Before I show you the S&P 500 with a Sector Rotation Model overlay, let’s briefly review the concept of sector rotation.

Sector rotation can be helpful in determining what the S&P 500 is likely (Read More….)

iKang Reportedly Receives $20 ADR Offer From China Life

June 17, 2016: iKang reportedly receives $20 per ADR offer from China Life (Yunfeng’s offer is $20-25/ADS).

Last August, a group led by Ligang Zhang, iKang’s founder, chairman and CEO submitted an initial going-private offer valued at $17.80/shr. Last November, it received a competing going-private offer from a group led by Jiangsu Sanyou (Read More….)